UroGen Pharma
URGN
128 hedge funds and large institutions have $446M invested in UroGen Pharma in 2024 Q3 according to their latest regulatory filings, with 25 funds opening new positions, 51 increasing their positions, 29 reducing their positions, and 12 closing their positions.
108% more first-time investments, than exits
New positions opened: 25 | Existing positions closed: 12
76% more repeat investments, than reductions
Existing positions increased: 51 | Existing positions reduced: 29
11% more funds holding
Funds holding: 115 → 128 (+13)
9.52% less ownership
Funds ownership: 92.94% → 83.42% (-9.5%)
31% less capital invested
Capital invested by funds: $641M → $446M (-$196M)
67% less funds holding in top 10
Funds holding in top 10: 3 → 1 (-2)
82% less call options, than puts
Call options by funds: $323K | Put options by funds: $1.83M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
+$6.47M |
| 2 |
VPC
Vestal Point Capital
New York
|
+$5.94M |
| 3 |
Morgan Stanley
New York
|
+$5.09M |
| 4 |
Millennium Management
New York
|
+$5.02M |
| 5 |
BlackRock
New York
|
+$4.51M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$51.7M |
| 2 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$31.9M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
-$14M |
| 4 |
CAC
Cowen and Company
New York
|
-$4.5M |
| 5 |
SCM
Silverarc Capital Management
Boston,
Massachusetts
|
-$2.98M |
URGN Hedge Fund Activity: Q3 2024 in Review
128 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in UroGen Pharma (URGN) for Q3 2024, worth a combined $446M — down 31% from $641M a quarter earlier.
Buyers outnumbered sellers: 25 funds opened new URGN positions and 12 closed out — a net gain of 13 holders — while 51 added to existing stakes and 29 trimmed.
The largest buyer was Adage Capital Partners, adding an estimated $6.47M. The largest seller was RA Capital Management, exiting entirely with an estimated $51.7M sold.
- 128 institutional investors held UroGen Pharma (URGN) as of Q3 2024, up from 115 in Q2 2024.
- Funds reported $446M of UroGen Pharma stock for Q3 2024, down 31% quarter-over-quarter.
- 25 funds opened new UroGen Pharma positions in Q3 2024 and 12 closed out, a net change of +13 holders.
- The largest UroGen Pharma buyer in Q3 2024 was Adage Capital Partners, an estimated $6.47M added.
- The largest UroGen Pharma seller in Q3 2024 was RA Capital Management, an estimated $51.7M sold.
Based on aggregated 13F filings for Q3 2024.